Rezera: ruvonoflast cuts inflammation added to semaglutide
Rezera Inc. has reported positive topline results from RESOLVE-2, its Phase 2 trial of ruvonoflast administered alongside semaglutide, saying the combination produced statistically significant additional reductions in the inflammatory marker high-sensitivity C-reactive protein compared with semaglutide alone.
The study enrolled 82 adults with obesity in a randomised, double-blind, placebo-controlled design over 32 weeks. All participants received once-weekly subcutaneous semaglutide titrated to 2.4 mg, with half also receiving oral ruvonoflast. Safety and tolerability were the primary objectives. The company reported no new safety signals and no imbalances in safety parameters, saying ruvonoflast's profile was consistent with its prior clinical experience.
Key efficacy findings
Among participants with a baseline hsCRP of 2 mg/L or above, a threshold widely used to indicate elevated residual inflammatory risk in cardiovascular disease, the combination more than doubled the probability of achieving hsCRP below that threshold compared with semaglutide alone. Weight loss was comparable across both arms in the overall population, a finding Rezera will likely use to argue the anti-inflammatory benefit is additive rather than secondary to greater weight reduction.
The results are consistent with data from RESOLVE-1, the company's earlier Phase 2 monotherapy study, in which ruvonoflast produced an 82% reduction in hsCRP alongside concordant reductions in IL-6, IL-18 and fibrinogen. Chief Medical Officer Jyothis George said the RESOLVE-2 data strengthen confidence in ruvonoflast's profile ahead of the company's previously announced Phase 3 programme in peripheral artery disease.
Marc Bonaca, Executive Director of the Colorado Prevention Center and Professor of Medicine at the University of Colorado Anschutz, noted that the STRIDE trial had shown semaglutide improved walking distance in patients with symptomatic PAD and diabetes, with those benefits hypothesised to be substantially mediated through anti-inflammatory mechanisms. He said the additive hsCRP reductions seen with ruvonoflast in combination support the rationale for NLRP3 inhibition in that population.
Market context and competitive landscape
Ruvonoflast is an oral small-molecule inhibitor of NLRP3, an inflammasome platform that has attracted considerable pharmaceutical interest over the past several years. Several companies, including Novartis with its intravenous agent ziltivekimab and a number of other clinical-stage biotechs, are pursuing anti-inflammatory strategies to address residual cardiovascular risk. The NLRP3 oral inhibitor space in particular features a growing number of programmes from both large pharma and specialist biotechs, though no agent in the class has yet achieved regulatory approval for a cardiovascular indication.
The combination approach with semaglutide is a notable strategic angle. GLP-1 receptor agonists have become the dominant therapeutic class in cardiometabolic disease following landmark outcome trials, and evidence that an NLRP3 inhibitor can deliver incremental inflammatory benefit on top of them could be commercially significant if borne out in Phase 3. Rezera's planned REVEAL-PAD study will be an important test of whether hsCRP reductions translate to functional and outcomes benefit in that underserved population.
Full RESOLVE-2 findings are expected to be presented at an upcoming medical conference and submitted to a peer-reviewed journal. Separately, RESOLVE-1 data will feature in a late-breaking presentation at the American Heart Association Scientific Sessions in Chicago on 6-9 November 2026.